BiotechTube

Nivolumab + Nab-paclitaxel + Nivolumab

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscle-Invasive Bladder Carcinoma

Conditions

Muscle-Invasive Bladder Carcinoma

Trial Timeline

Jan 27, 2022 → Jun 1, 2025

NCT ID
NCT04876313

About Nivolumab + Nab-paclitaxel + Nivolumab

Nivolumab + Nab-paclitaxel + Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Muscle-Invasive Bladder Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04876313. Target conditions include Muscle-Invasive Bladder Carcinoma.

What happened to similar drugs?

0 of 3 similar drugs in Muscle-Invasive Bladder Carcinoma were approved

Approved (0) Terminated (0) Active (3)
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
🔄Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
🔄AtezolizumabRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04876313Phase 2UNKNOWN

Competing Products

12 competing products in Muscle-Invasive Bladder Carcinoma

See all competitors
ProductCompanyStageHype Score
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
44
Durvalumab (Imfinzi) + TremelimumabAstraZenecaPhase 2
27
Pembrolizumab + GemcitabineMerckPhase 2
39
Chemotherapy + Immunotherapy Induction + Immunotherapy MaintenanceMerckPhase 2
42
Autogene Cevumeran + Nivolumab + SalineRochePhase 2
42
AtezolizumabRochePhase 3
44
Cretostimogene GrenadenorepvecCG OncologyPhase 2
39
CG0070 + NivolumabCG OncologyPhase 1
26
AU-011Aura BiosciencesPhase 1
26
REOLYSIN® + Gemcitabine + CisplatinOncolytics BiotechPhase 1
11